Genetic testing for personalized medication in stroke patients
Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing in Patients With Minor Stroke or High Risk TIA (CYP2C19 and Stroke)
This study is testing if using genetic testing can help doctors choose the best medication for stroke patients to improve their treatment and recovery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 89 Years |
| Sex | All |
| Sponsor | University of Alabama at Birmingham Academic / other |
| Locations | 1 site (Birmingham, Alabama) |
| Trial ID | NCT06943586 on ClinicalTrials.gov |
What this trial studies
This pilot clinical trial investigates the feasibility of using CYP2C19 genetic testing to guide dual antiplatelet therapy (DAPT) for patients experiencing minor ischemic strokes or high-risk transient ischemic attacks (TIAs). The study aims to determine if personalized medicine can enhance medication decisions made by physicians during hospital stays. By assessing patients' genetic profiles, the trial seeks to optimize treatment strategies and improve outcomes for this vulnerable population.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-89 who are admitted to the hospital with symptoms of minor ischemic stroke or high-risk TIA and can receive dual antiplatelet therapy.
Not a fit: Patients with conditions such as atrial fibrillation, valvular heart disease, or those who have received certain treatments like intravenous thrombolysis may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and tailored medication regimens for stroke and TIA patients, potentially improving recovery and reducing complications.
How similar studies have performed: While this approach is innovative, similar studies exploring pharmacogenomics in other conditions have shown promise, suggesting potential for success in this context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients 18-89 years of age * admitted to University of Alabama at Birmingham (UAB) main hospital with symptoms or signs of minor ischemic stroke, or high risk TIA * eligible to receive dual antiplatelet load (presented to the hospital within 66 hours of last known well) Exclusion Criteria: * diagnosis of atrial fibrillation, valvular heart disease, index stroke due to known hypercoagulability (subset of other determined etiology) or large vessel disease (culprit vessel stenosis of ≥50%) * prescribed anticoagulation prior to stroke * treated with intravenous thrombolysis * treated with mechanical thrombectomy * missing NIH Stroke Scale score
Where this trial is running
Birmingham, Alabama
- University of Alabama at Birmingham — Birmingham, Alabama, United States (Recruiting)
Study contacts
- Principal investigator: Ekaterina Bakradze, MD — University of Alabama at Birmingham
- Study coordinator: Ekaterina Bakradze, MD
- Email: ebakradze@uabmc.edu
- Phone: 205-975-8569
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.